HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BlueRock Therapeutics

Division of Bayer AG
www.bluerocktx.com

Latest From BlueRock Therapeutics

Start-Up Quarterly Statistics: Financings Continue Quarterly Declines Despite Big Venture Deals And IPOs

A review of biopharma start-up dealmaking and financing activity from July through September 2019, based on data from Strategic Transactions. Fundraising activity fell 23% from the second to the third quarter, but start-up M&A surged, led by Vertex's acquisition of Semma. 

Financing Deals

Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease

Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
Deals M & A

Venture Funding Deals: July Sees Seven Rounds Of $100m Or More

Century Therapeutics brings in $250m for its cell therapy programs in a series A round, while immunotherapy specialist BioNTech sets a record for series B, raising $350m. Another five firms brought in rounds of $100m or greater...

Deals Financing

Bayer Eyes Indications Beyond BlueRock's Initial Focus With $240m-Plus Buyout

Bayer will acquire the 40.8% of BlueRock that it doesn't already own as the firm's largest investor via a $225m series A round in 2016. A clinical trial for BlueRock's Parkinson's disease candidate is expected to begin later this year.

Deals M & A
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Immune Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Bayer AG
  • Senior Management
  • Emile Nuwaysir, PhD, Pres. & CEO
    Shane Kovacs, CBO & CFO
    Joachim Fruebis, PhD, Chief Dev. Officer
  • Contact Info
  • BlueRock Therapeutics
    1 Broadway
    Cambridge, MA 02142
    USA
UsernamePublicRestriction

Register